Ratings by Barclays (Carter Gould)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/19/2026 | Amgen | AMGN | New Coverage | Equalweight (N/A) |
379.73 (369.53) |
-2.69% | Details | |
| 2/19/2026 | Biogen | BIIB | New Coverage | Equalweight (N/A) |
194.13 (184.87) |
-4.77% | Details | |
| 2/19/2026 | Gilead Sciences | GILD | New Coverage | Equalweight (N/A) |
152.74 (143.93) |
-5.77% | Details | |
| 2/19/2026 | Abbvie | ABBV | New Coverage | Overweight (N/A) |
228.72 (230.11) |
0.61% | Details | |
| 2/19/2026 | Merck | MRK | New Coverage | Overweight (N/A) |
121.66 (115.79) |
-4.82% | Details | |
| 2/19/2026 | Pfizer | PFE | New Coverage | Underweight (N/A) |
27.37 (27.05) |
-1.17% | Details | |
| 12/23/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2024 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2024 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/7/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/1/2024 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2024 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/24/2024 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/23/2024 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/7/2024 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/7/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 10/7/2024 | Amgen | AMGN | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 10/7/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2024 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/22/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 8/14/2024 | Vor Biopharma, Inc. | VOR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2024 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2024 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2024 | Bristol-Myers Squibb Co. | BMY | Downgrade | Underweight (Equalweight) |
50.45 (60.29) |
19.5% | Details | |
| 7/26/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2024 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/10/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/13/2024 | Barinthus Biotherapeutics | BRNS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/23/2024 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Amgen | AMGN | Upgrade | Equalweight (Underweight) |
277.37 (369.53) |
33.23% | Details | |
| 5/2/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/29/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/25/2024 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/4/2024 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/27/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2024 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/12/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/5/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2024 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2024 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/23/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2024 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/23/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2024 | Allakos Inc. | ALLK | Maintain | Underweight (N/A) |
|
Details | ||
| 12/19/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/14/2023 | Allakos Inc. | ALLK | Maintain | Underweight (N/A) |
|
Details | ||
| 11/8/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/1/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/30/2023 | Abbvie | ABBV | Upgrade | Overweight (Equalweight) |
145.20 (230.11) |
58.48% | Details | |
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/2/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/2/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/2/2023 | Amgen | AMGN | Maintain | Underweight (N/A) |
|
Details | ||
| 9/22/2023 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/21/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2023 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2023 | Reata Pharmaceuticals | RETA | Downgrade | Equalweight (Overweight) |
167.19 (172.36) |
3.09% | Details | |
| 7/24/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Amgen | AMGN | Maintain | Underweight (N/A) |
|
Details | ||
| 7/7/2023 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/28/2023 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/28/2023 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2023 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Alector Inc. | ALEC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/1/2023 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/1/2023 | Amgen | AMGN | Maintain | Underweight (N/A) |
|
Details | ||
| 4/26/2023 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/14/2023 | Amgen | AMGN | Maintain | Underweight (N/A) |
|
Details | ||
| 4/13/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/13/2023 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/27/2023 | Vor Biopharma, Inc. | VOR | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/21/2023 | Gossamer Bio Inc. | GOSS | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/21/2023 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/1/2023 | Amgen | AMGN | Maintain | Underweight (N/A) |
|
Details | ||
| 1/18/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/18/2023 | Amgen | AMGN | Maintain | Underweight (N/A) |
|
Details | ||
| 12/7/2022 | Gossamer Bio Inc. | GOSS | Downgrade | Equalweight (Overweight) |
9.29 (0.50) |
-94.62% | Details | |
| 11/30/2022 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/11/2022 | Vor Biopharma, Inc. | VOR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2022 | Applied Therapeutics | APLT | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/2/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2022 | Amgen | AMGN | Downgrade | Underweight (Equalweight) |
267.23 (369.53) |
38.28% | Details | |
| 10/31/2022 | Gilead Sciences | GILD | Upgrade | Equalweight (Underweight) |
70.20 (143.93) |
105.03% | Details | |
| 10/28/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2022 | Gilead Sciences | GILD | Maintain | Underweight (N/A) |
|
Details | ||
| 10/12/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/7/2022 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2022 | Applied Therapeutics | APLT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/5/2022 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/29/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2022 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/11/2022 | Allakos Inc. | ALLK | Maintain | Underweight (N/A) |
|
Details | ||
| 5/11/2022 | Alector Inc. | ALEC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2022 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/4/2022 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/2/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/26/2022 | Gossamer Bio Inc. | GOSS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2022 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/21/2022 | Vor Biopharma, Inc. | VOR | Maintain | Overweight (N/A) |
|
Details | ||
| 3/21/2022 | Applied Therapeutics | APLT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2022 | Gilead Sciences | GILD | Maintain | Underweight (N/A) |
|
Details | ||
| 2/16/2022 | Allakos Inc. | ALLK | Maintain | Underweight (N/A) |
|
Details | ||
| 2/9/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/7/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2022 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/20/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2022 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/4/2022 | Applied Therapeutics | APLT | Downgrade | Equalweight (Overweight) |
8.95 (0.10) |
-98.88% | Details | |
| 12/22/2021 | Allakos Inc. | ALLK | Maintain | Underweight (N/A) |
|
Details | ||
| 12/10/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2021 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/1/2021 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2021 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/8/2021 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/8/2021 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/1/2021 | Acceleron Pharma | XLRN | Downgrade | Equalweight (Overweight) |
175.36 (178.75) |
1.93% | Details | |
| 8/6/2021 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/20/2021 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2021 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/26/2021 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2021 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Equalweight) |
91.50 (128.13) |
40.03% | Details | |
| 5/5/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/30/2021 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2021 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/18/2021 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
21.86 (37.81) |
72.96% | Details | |
| 2/16/2021 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2020 | Acceleron Pharma | XLRN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2020 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/29/2020 | Gilead Sciences | GILD | Maintain | Underweight (N/A) |
|
Details | ||
| 10/29/2020 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/22/2020 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2020 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2020 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/29/2020 | Alector Inc. | ALEC | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2020 | Biogen | BIIB | Downgrade | Equalweight (Overweight) |
260.30 (184.87) |
-28.98% | Details | |
| 6/1/2020 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/13/2020 | Gossamer Bio Inc. | GOSS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2020 | Gilead Sciences | GILD | Maintain | Underweight (N/A) |
|
Details | ||
| 4/29/2020 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/29/2020 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2020 | Gilead Sciences | GILD | New Coverage | Underweight (N/A) |
74.70 (143.93) |
92.68% | Details | |
| 2/27/2020 | Pfizer | PFE | New Coverage | Equalweight (N/A) |
34.72 (27.05) |
-22.09% | Details | |
| 2/27/2020 | Neurocrine Bio. | NBIX | New Coverage | Equalweight (N/A) |
93.95 (128.13) |
36.38% | Details | |
| 2/27/2020 | Abbvie | ABBV | New Coverage | Equalweight (N/A) |
88.41 (230.11) |
160.28% | Details | |
| 2/27/2020 | Amgen | AMGN | New Coverage | Equalweight (N/A) |
214.54 (369.53) |
72.24% | Details | |
| 2/27/2020 | Bristol-Myers Squibb Co. | BMY | New Coverage | Equalweight (N/A) |
62.04 (60.29) |
-2.82% | Details | |
| 2/27/2020 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
457.92 (787.50) |
71.97% | Details | |
| 2/27/2020 | Merck | MRK | New Coverage | Overweight (N/A) |
79.94 (115.79) |
44.85% | Details | |
| 2/27/2020 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
13.93 (0.50) |
-96.41% | Details | |
| 2/27/2020 | Callaway Golf | ELY | New Coverage | Overweight (N/A) |
16.91 (21.33) |
26.14% | Details | |
| 2/27/2020 | Biogen | BIIB | New Coverage | Overweight (N/A) |
327.45 (184.87) |
-43.54% | Details | |
| 2/27/2020 | Alector Inc. | ALEC | New Coverage | Overweight (N/A) |
27.41 (2.00) |
-92.7% | Details | |
| 2/27/2020 | Acceleron Pharma | XLRN | New Coverage | Overweight (N/A) |
87.36 (178.75) |
104.61% | Details |
